Okami Medical Highlights Clinical Momentum for LOBO System at SIR2026

A LinkedIn post from Okami Medical centers on the conclusion of the SIR2026 conference and emphasizes clinical work related to the company’s LOBO vascular occlusion system. The post specifically recognizes teams at the University of North Carolina and the University of Chicago for contributions described as advancing the clinical body of evidence for LOBO.

The post also highlights engagement with clinicians through a booth presence, lunch symposium, hands-on workshop, and technology suite demonstrations at the event. For investors, this activity suggests continued efforts to build clinical adoption and physician familiarity, which could be important for long-term procedure volume, reimbursement support, and competitive positioning in the vascular occlusion segment.

While no new financial data, commercial milestones, or regulatory developments are mentioned, the focus on clinical evidence and practitioner outreach may signal an emphasis on strengthening real-world validation of the LOBO system. Sustained participation in major specialty conferences such as SIR could help Okami Medical reinforce its brand and support future commercialization or partnership opportunities in interventional radiology.